Efficacy and safety of ospemifene in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women: A phase II dose ranging, 12-week, randomized , double-blind, placebo-controlled, parallel-group study comparing oral ospemifene 5 mg, 15 mg and 30 mg daily doses with placebo.
Phase of Trial: Phase II
Latest Information Update: 14 Jul 2016
At a glance
- Drugs Ospemifene (Primary)
- Indications Atrophic vaginitis
- Focus Therapeutic Use
- Acronyms VVA-study
- Sponsors Hormos Medical; Shionogi
- 29 Mar 2008 New trial record.